Investors Set October Deadline for Aardvark Therapeutics Lawsuit

The litigation centers on allegations that Aardvark Therapeutics issued a registration statement and prospectus in connection with its February 2025 IPO that contained materially false or misleading information. The complaint claims the company failed to disclose critical adverse facts regarding the safety profile of its drug candidate, ARD-101. According to the filing, these omissions led investors to hold an inflated view of the drug's clinical, regulatory, and commercial viability. When the underlying details regarding ARD-101 reached the market, the value of the company’s securities reportedly declined, causing financial losses for shareholders.

Investors wishing to participate in the litigation are not currently represented by counsel unless they choose to retain an attorney. While the deadline to move the court for lead plaintiff status is October 13, 2026, participation in any future recovery does not strictly require serving in this representative capacity. Interested parties may contact Phillip Kim at the Rosen Law Firm for further information regarding the case and their legal options.